

2019

**Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: A systematic review**

Philippa J. May

Steven Y.C Tong

Andrew C. Steer

Bart J. Currie

Ross M. Andrews

*See next page for additional authors*

Follow this and additional works at: [https://researchonline.nd.edu.au/health\\_article](https://researchonline.nd.edu.au/health_article)



Part of the [Life Sciences Commons](#), and the [Medicine and Health Sciences Commons](#)

This article was originally published as:

May, P. J., Tong, S. Y., Steer, A. C., Currie, B. J., Andrews, R. M., Carapetis, J. R., & Bowen, A. C. (2019). Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: A systematic review. *Tropical Medicine and International Health*, 24 (3), 280-293.

Original article available here:

[10.1111/tmi.13198](https://doi.org/10.1111/tmi.13198)

This article is posted on ResearchOnline@ND at [https://researchonline.nd.edu.au/health\\_article/258](https://researchonline.nd.edu.au/health_article/258). For more information, please contact [researchonline@nd.edu.au](mailto:researchonline@nd.edu.au).



---

**Authors**

Philippa J. May, Steven Y.C Tong, Andrew C. Steer, Bart J. Currie, Ross M. Andrews, Jonathan R. Carapetis, and Asha C. Bowen

This article has been published in *Tropical Medicine and International Health*.

Published by John Wiley & Sons Ltd.

Available at: <https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13198>

This is an Open Access article distributed in accordance with the Creative Commons Attribution 4.0 International license (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

See: <https://creativecommons.org/licenses/by/4.0/>

May, P.J., Tong, S.Y.C., Steer, A.C., Currie, B.J., Andrews, R.M., Carapetis, J.R., and Bowen, A.C. (2019) Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: A systematic review. *Tropical Medicine and International Health*, 24(3), 280-293. doi: 10.1111/tmi.13198

## Systematic Review

# Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review

Philippa J. May<sup>1</sup>, Steven Y. C. Tong<sup>2,3</sup>, Andrew C. Steer<sup>4,5</sup>, Bart J. Currie<sup>3,6</sup>, Ross M. Andrews<sup>3,7</sup>, Jonathan R. Carapetis<sup>8,9,10</sup> and Asha C. Bowen<sup>3,8,9,10,11</sup>

1 Northern Territory Centre for Disease Control, Casuarina, Australia

2 Victorian Infectious Diseases Service, Royal Melbourne Hospital, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Australia

3 Menzies School of Health Research, Charles Darwin University, Casuarina, Australia

4 Royal Children's Hospital, Parkville, Australia

5 Murdoch Children's Research Institute, University of Melbourne, Parkville, Australia

6 Royal Darwin Hospital, Casuarina, Australia

7 National Centre for Epidemiology & Population Health, Australian National University, Canberra, Australia

8 Perth Children's Hospital, Nedlands, Australia

9 Wesfarmers Centre for Vaccines and Infectious Diseases, University of Western Australia, Nedlands, Australia

10 School of Medicine, University of Western Australia, Nedlands, Australia

11 University of Notre Dame Australia, Fremantle, Australia

## Summary

We conducted a systematic review of the treatment, prevention and public health control of skin infections including impetigo, scabies, crusted scabies and tinea in resource-limited settings where skin infections are endemic. The aim is to inform strategies, guidelines and research to improve skin health in populations that are inequitably affected by infections of the skin and the downstream consequences of these. The systematic review is reported according to the PRISMA statement. From 1759 titles identified, 81 full text studies were reviewed and key findings outlined for impetigo, scabies, crusted scabies and tinea. Improvements in primary care and public health management of skin infections will have broad and lasting impacts on overall quality of life including reductions in morbidity and mortality from sepsis, skeletal infections, kidney and heart disease.

**keywords** impetigo, scabies, crusted scabies, tinea

## Introduction

Children in developing countries and other resource-limited settings bear a disproportionate burden of skin infections, owing to poverty, poorer living conditions, normalisation and limited access to primary healthcare [1–4]. More than 162 million children are estimated to have impetigo at any one time [5] and more than 110 million children with scabies [6]. There are no estimates for the global burden of tinea in children, although fungal skin infections were the leading skin disease and placed in the top 10 most prevalent diseases worldwide in 2010 [7].

Primary infection with impetigo and secondary bacterial infection of scabies, crusted scabies and tinea with

the bacteria *Staphylococcus aureus* and *Streptococcus pyogenes* (Group A Streptococcus, GAS) lead to morbidity, mortality and socioeconomic costs via invasive infection [8, 9]. Invasive *S. aureus* has a global incidence estimate of 20–50 cases/100 000 population per year with a case fatality rate of 5–30% [10, 11]. An estimated 163 000 people die from GAS bacteraemia each year [8]. Moreover, post-streptococcal sequelae of acute rheumatic fever (ARF) and acute post-streptococcal glomerulonephritis (APSGN) can lead to long-term consequences of chronic heart and kidney disease [8, 12, 13]. Due to differences in the social determinants of health, there exists a marked disparity in the burden of skin infections and their sequelae between resource-rich and resource-limited settings [14].

Systematic reviews of skin infection treatments that have only included randomised clinical trials (RCT) [15–18], exclude a large body of available evidence from resource-limited settings where the burden is highest [5–7]. RCTs are often conducted in hospital outpatient departments (OPD) in high-income settings, and findings may not be directly applicable to resource-limited settings where cultural practices, access, availability, cost and acceptability of treatments may differ. There remains a lack of consensus on the best treatments and population health approaches for the prevention and control of skin infections, both individual skin conditions and skin infections collectively, in these resource-limited settings due to a lack of a review of the evidence that is externally valid to these populations. We conducted a systematic review of studies from resource-limited and endemic settings regarding the prevention, treatment and public health management of impetigo, scabies, crusted scabies and tinea to inform the development of evidence-based guidelines and future research priorities for skin infections in endemic populations.

## Methods

### Search strategy and selection criteria

This systematic review is reported according to the Preferred Reporting items for Systematic Reviews and Meta-Analyses (PRISMA) statement [19]. The methods and search strategy have been described previously [20]. Briefly peer reviewed and grey literature databases were searched. Studies published in English since 1960 using any experimental study (RCTs, clinical controlled trials, before and after studies and interrupted time series analyses) or observational study design (cohort and ecological studies) were included. Eligible participant types included Indigenous peoples and populations in resource-limited settings (low, low-middle and middle-income countries and resource-limited populations in Organisation for Economic Co-operation and Development (OECD) countries) (see Appendix S1 for definitions) with a diagnosis of impetigo, scabies, crusted scabies, tinea capitis, tinea corporis or tinea unguium (onychomycosis) in persons of any age or sex. We reviewed any clinical or public health interventions aiming to reduce skin infections with any type of comparator. Outcomes were categorised as primary (cure or decrease in prevalence for population-based studies) or secondary (microbiological cure, symptom relief, recurrence, adherence, acceptability, adverse events and spread to contacts).

Two authors (AB and PM) independently screened the titles and abstracts of all studies identified in the search process and selected the studies for eligibility assessment. Full reports of these studies were obtained and assessed by two independent reviewers (10 reviewers in total). Any discrepancies for inclusion were resolved by consensus discussion.

### Assessment of methodological quality and data extraction

Two reviewers independently scored for methodological quality of clinical trials using *The Cochrane Collaboration's tool for assessing risk of bias* [21]. Observational studies were assessed for blinding, completeness of outcome data, outcome reporting and other sources of bias including confounders. All data were entered into data extraction forms using Covidence online software (Veritas Health Innovation, Melbourne, VIC, Australia) by the two independent reviewers and discrepancies resolved via discussion.

### Statistical analysis and synthesis

The data are presented in a narrative synthesis. Meta-analysis was not performed due to the heterogeneity of studies. Calculations were performed using STATA13 (Statacorp, Texas, USA). For reading ease, results are presented in common theme groups in each area of clinical treatment or public health prevention and control relevant to skin infections in resource-limited settings. As many population-based studies incorporate multiple strategies such as health education, treatment and hygiene practices, it is recommended that all evidence is considered by the reader as a whole. We used the GRADE approach to rate evidence across studies for specific clinical outcomes to link evidence-quality evaluations to recommendations in clinical guidelines (Table 1).

## Results

The search strategy identified 1759 titles and 455 abstracts for screening, of which 193 met the inclusion criteria. 81 full text studies were included (Figure 1), representing >27 633 participants over a 40-year period (1976–2015). The study size, type, location and condition under study are summarised (Figure 2, Table S1). The study details and characteristics are summarised in Table 2. There were 44 (54%) RCTs, four (5%) cluster RCTs, three (4%) controlled clinical trials, three (4%) controlled before and after studies and three (4%) controlled population studies (Table S2). There were two

**Table 1** Grading of recommendations assessment, development and evaluation evidence grades and strength of recommendations

Code	Quality of evidence	Definition
A	High	Further research is very unlikely to change the level of confidence in the estimate of effect. <i>i.e.</i> <ul style="list-style-type: none"> <li>• Several high-quality studies with consistent results</li> </ul>
B	Moderate	Further research is likely to have an impact in current confidence in the estimate of effect and may change the estimate. <i>i.e.</i> <ul style="list-style-type: none"> <li>• One high-quality study</li> <li>• Several studies with some limitations</li> </ul>
C	Low	Further research is very likely to have an important impact on the level of confidence in the estimate of effect and would likely change the estimate. <i>i.e.</i> <ul style="list-style-type: none"> <li>• One or more studies with severe limitations</li> </ul>
D	Very Low	Estimate of effect is very uncertain. <i>i.e.</i> <ul style="list-style-type: none"> <li>• No direct research evidence</li> <li>• One of more studies with very severe limitations</li> </ul>

Code	Strength of recommendation	Implications when combined with evidence grade
1	Strong	1A: Strong recommendation, applies to most patients without reservation. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present. 1B: Strong recommendation, applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present. 1C: Strong recommendation, applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality. 1D: * Strong recommendation, applies to most patients. However, the recommendation is based on expert consensus only.
2	Weak	2A: Weak recommendation and best action may differ depending on circumstances or patients or societal values. 2B: Weak recommendation and alternative approaches likely to be better for some patients under some circumstances. 2C: Very weak recommendation; other alternatives may be equally reasonable. 2D: * Very weak recommendation based on expert consensus. Further research is necessary.

\*1D and 2D recommendations are not routinely included by the GRADE approach as these are based on expert consensus, rather than scientific evidence. These additional recommendation grades were created due to lack of available supporting evidence but an identified need to make recommendations to guide clinical and public health management.


(3%) before and after studies, four (5%) ecological studies, 14 (17%) prospective cohort studies and four (5%) retrospective observational studies appraised (Table S3).

#### Summary of clinical treatment recommendations for resource-limited settings

*Comprehensive community skin health programmes.* Moderate quality evidence that treatment combined with comprehensive skin control measures (health promotion, environmental interventions and screening) add benefit in sustaining a reduction in scabies prevalence alone (2B) [22] and impetigo and scabies prevalence combined (2C) (Appendix S2) [23–25]. No studies assessed the effect of a community skin health programme on impetigo

or tinea alone, whilst one study described this for scabies [22], one for scabies and impetigo [23, 24], and one for general skin infections [25]. High-quality evidence from studies using control communities would be advantageous in determining the measurable benefit over standard treatment (Table 3).

In Bangladesh, moderate quality evidence was provided from a study where permethrin Mass Drug Administration (MDA) was followed by randomisation of male boarding school students to a scabies control programme (repeat permethrin treatment for scabies, health promotion activities with a designated scabies class monitor, daily bathing with soap and bags for bedding and clothing storage) or control [22]. At 4 months, scabies prevalence was 5% (intervention) and 50% (control),  $P < 0.001$  [22]. In Australia, low-




**Figure 1** PRISMA flow diagram for study selection in the systematic review.

quality evidence was provided from a permethrin MDA that included a comprehensive skin control programme (annual treatment and community clean up days, health promotion and repeat treatment with permethrin for scabies) in a remote Indigenous community [23, 24]. Scabies prevalence declined from 35% to 12%,  $P < 0.0001$  and impetigo from 11% to 2%,  $P = 0.0005$  [23, 24]. In Kenya, low-quality evidence was provided from a 5-year dermatology project

within primary healthcare (training of healthcare workers and school-based treatments) that did not show a sustained reduction in impetigo, scabies or tinea [25].

**Impetigo.** Directed antimicrobial therapy. High-quality evidence supports the use of oral co-trimoxazole or intramuscular (IM) benzathine penicillin G (BPG) for the treatment of impetigo (1A) [26, 27]. Oral amoxicillin or oral erythromycin are suitable alternatives (2B) [28]. Oral



**Figure 2** Selected summary characteristics of studies included in the systematic review. [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)].

**Table 2** Number of studies in each broad intervention group by skin condition. Gaps in the evidence are shown as grey boxes

Intervention	Condition						Total number of studies
	Impetigo	Scabies	Scabies and impetigo	Crusted scabies	Fungal skin infections	Multiple skin conditions under study or 'skin infections' that were not otherwise specified	
Comprehensive community skin health programmes		1	1			1	3
Coordinated case management				1			1
Standard treatment protocols				1			1
Directed clinical treatment	4	19		1	23		47
Mass Drug Administration		4	9				13
Complimentary/alternative therapy		2			1	1	4
Communicable disease control*		3					3
Hygiene practices‡	2				1		3
Water provision†	1		1			2	4
Housing programmes						2	2
<b>Total</b>	<b>7</b>	<b>29</b>	<b>11</b>	<b>3</b>	<b>25</b>	<b>6</b>	<b>81</b>

\*Communicable disease control activities= outbreak response or treatment of contacts.

†Water provision = swimming pools or clean water supply to homes.

‡Hygiene practices = provision of soap and hand-washing education.

penicillin G is not recommended for treatment of impetigo (2D) [29]. Although topical antibiotics are recommended as the preferred treatment for impetigo in

industrialised settings [16], there is no available evidence from resource-limited contexts for topical antibiotics or evidence to not treat impetigo.



**Table 3** Number of included studies with public health co-interventions for skin infections

Skin condition	Public health co-interventions	Treatment of contacts	Promotion of regular bathing and/or hand-washing	Health education	Washing of clothing and bed linen	Storage of items in plastic bags	Exposing items to direct sunlight	Household spraying
Impetigo	2		2	1				
Scabies	22	14	2	6	12	2	4	1
Scabies and impetigo	5	1	1	3	2		1	1
Crusted scabies								
Fungal skin infections	1		1					
General skin infections	4		2	2				
Total	34	15	8	12	14	2	5	2

\*Total does not equate to 81 studies as some studies had more than one public health intervention. Grey shades represent missing data i.e., nothing known for these categories.

High-quality evidence from two open label RCTs with Australian Indigenous children compared oral cotrimoxazole *vs.* IM BPG and found no difference in clinical or microbiological cure of impetigo [26, 27]. Moderate quality RCT evidence reported clinical cure in 89% of patients in both groups when oral amoxicillin and oral erythromycin for 7 days in Mali were compared [28]. Low-quality RCT evidence in Canadian Indigenous children compared oral penicillin G for 10 days with IM BPG, with treatment failure equivalent: 16% and 14% respectively [29]. No studies assessed topical agents or used a placebo-controlled design for impetigo.

Mass Drug Administration. No studies assessed MDA for impetigo alone. Impetigo was a secondary outcome in scabies MDAs reported below.

Complimentary/alternative therapies. No studies assessed complimentary therapies for impetigo.

Hand-washing and hygiene practices. High-quality evidence supports daily hand-washing with soap for the treatment and prevention of impetigo, with no benefit found for antibacterial soap over regular soap (1A) [30, 31].

In Pakistan, high-quality evidence from two RCTs enrolling households with children assessed hand-washing with soap for impetigo and found a benefit for soap, but no difference between antibacterial (triclocarbon 1.2%) and standard soap [30, 31].

*Scabies.* All studies on scabies treatment used clinical cure or symptom relief as end points.

Directed anti-parasitic therapy. Topical treatment *vs.* topical treatment—Seven studies compared topical anti-parasitic agents for scabies [32–38], with low to moderate quality evidence for either topical permethrin or topical ivermectin (2B) [32, 33]. Permethrin is superior to lindane (1A) [34], topical crotamiton (2C)[35] or Tenutex emulsion (disulphiram and benzyl benzoate [BB]) in those >4 years (2C) [36]. Topical ivermectin is superior to topical crotamiton in those >2 years (2C) [37]. Very low-quality evidence from one study shows that topical BB or topical permethrin is safe in pregnant women (2C) [38]. Without high-quality evidence to support modified applications of topical treatments for scabies, the standard whole-body application remains strongly recommended (1D).

High-quality RCT evidence from an Iranian hospital OPD found that two applications of 5% permethrin achieved a superior clinical cure (85%) compared to 1% lindane (49%),  $P < 0.05$  [34]. Clinical cure was similar with topical ivermectin or topical permethrin in an Iranian dermatology OPD [33]. When topical ivermectin 1% and topical permethrin 5% were compared with oral ivermectin, clinical response at 1 week was superior with either topical treatment (69% and 75% *vs.* 30%,  $P < 0.05$ ) whilst cure at 4 weeks was universal for all three agents [32]. Topical permethrin [35] and topical ivermectin [37] were superior to topical crotamiton at 4 weeks follow-up. Topical permethrin was superior to Tenutex emulsion [36]. Very low-quality evidence from a refugee camp on the Thai-Burmese border assessed safety of permethrin and BB in pregnancy [38].

## Modified application of permethrin

Practice point Box: How is it best to apply topical scabicides?

Twenty-nine studies incorporated a topical scabicide/s, mostly permethrin. (Table S4). One study directly compared neck to toe application (head to toe in children) with application to lesions only [39]. Overall, head to toe or neck to toe was recommended in 26 studies, lesion only in four (three of which were topical ivermectin and not specified in seven studies). Full body application of topical scabicides is recommended (1D). The effective application of topical scabicides requires a private setting where the clothes can be removed for application. This is not always practical or achievable in overcrowded households and may limit the effect of topical therapy.

Oral treatment *vs.* topical treatment—Moderate to high-quality evidence supports the use of oral ivermectin or topical permethrin for the treatment of scabies (1A) [32, 40–42].

A comparison of topical 5% permethrin with oral ivermectin in a high-quality RCT from India found lesion count and pruritus significantly lower for permethrin at 1 week whilst clinical cure at 4 weeks was the same [40]. Moderate quality evidence from India reached similar conclusions [32]. From Iran, low-quality evidence is provided from two studies that compared oral ivermectin with topical permethrin and found superior symptom relief with permethrin at 2 weeks, whilst clinical cure was the same [41, 42]. There is moderate-high-quality evidence that oral ivermectin achieved superior clinical cure than topical lindane [43–45] or topical sulphur [46]. Comparisons of oral ivermectin with topical BB showed discrepant results: no difference in clinical cure based on high-quality RCT evidence from Vanuatu [47] whilst oral ivermectin was superior for clinical cure in moderate quality evidence from Senegal [48] and Nigeria [49].

Mass drug administration. There is moderate quality evidence for MDA to control scabies in resource-limited communities (1B) [50–53], with high-quality comparison RCTs needed to determine the best agent. Moderate quality evidence for the population effect of MDA for scabies on scabies and impetigo prevalence was achieved using either topical permethrin or oral

ivermectin (1B) [23, 54–56]. Oral ivermectin is superior to topical permethrin and standard of care for community-wide use in children >5 years and non-pregnant adults in isolated settings with high prevalence of scabies and impetigo (1B) [57]. High-quality studies conducted in mainland populations are required to determine the effectiveness of the MDA approach in highly mobile populations.

Scabies only—Low to moderate quality evidence from four studies in Fiji [50], India [52, 53] and Tanzania [51] assessed MDA impact on scabies prevalence only. Two doses of oral ivermectin achieved a 95% reduction in scabies in India [52] whilst single dose ivermectin MDA was not superior to BB in Fiji [50]. Ivermectin delivered in a lymphatic filariasis MDA reported a 68–98% decline in scabies [51]. When 25% BB was delivered in an MDA to an Indian orphanage, cure was 100% at 6 weeks [53].

Scabies and impetigo—*Permethrin MDA*—Low-quality evidence is provided from permethrin MDA's, which were all ecological in design with different populations reviewed at baseline and follow-up. Four studies from Panama [56] and remote Australian Aboriginal communities [23, 54, 55] showed a reduction in scabies and impetigo prevalence following MDA with 5% permethrin. The first scabies MDA used permethrin in a remote Kuna Indian population in Panama in 1986 and although interrupted by political tensions demonstrated a sustained response [56]. The permethrin MDAs were combined with impetigo treatment and broad-based community skin programmes including surveillance, health promotion, home cleaning and retreatment of cases in Australia [23, 54, 55].

*Ivermectin vs. Permethrin MDA*—Moderate quality evidence is provided from a cluster RCT where oral ivermectin and topical permethrin MDAs were compared with standard case treatment with topical permethrin for scabies in three Fijian island communities [57]. Ivermectin was superior at 12 months for scabies and impetigo [57].

*Ivermectin MDA*—Low-quality evidence is provided from two studies that assessed the effect of oral ivermectin MDA on scabies prevalence [58, 59]. In the Solomon Islands, two doses of oral ivermectin reduced the prevalence of scabies at 3 years [59] and this was sustained at a further follow-up 15 years later [60]. In contrast, an oral ivermectin MDA delivered in a remote Australian Aboriginal community did not show significant or sustained declines in scabies prevalence [58].

*Azithromycin MDA*—Very low-quality evidence from an azithromycin MDA for trachoma in a remote Australian Aboriginal population reported impetigo reduction at 2–3 weeks which returned to baseline at 6 months [61].

Scabies prevalence was unchanged [61].

Complimentary therapy. Moderate quality evidence that cold cream can be used as an adjunct to topical sulphur for scabies (2B) [62].

In a Mexican orphanage RCT, topical 10% sulphur in pork fat was compared with topical 10% sulphur in cold cream with high rates of cure [62]. Preliminary data for aloe vera for scabies treatment [63].

Communicable disease control and prevention. There is low-quality evidence for treatment of household contacts for the community control of scabies (2C) [64]. Treatment of cases and contacts is recommended in scabies outbreaks (2C), however, high-quality studies comparing treatments during outbreaks are required.

Low-quality evidence for the treatment of household contacts as the primary intervention for scabies control from one cohort of Australian Aboriginal households where a sixfold reduction in scabies in compliant households was found [64]. Fifteen other studies treated close contacts, family members or the household as co-interventions for scabies, however, without a comparison group, the effect cannot be reliably assessed. Moderate quality evidence found that oral ivermectin halted a scabies outbreak amongst healthcare workers and patients in Peru [65], and topical BB for cases and contacts with community education terminated an outbreak in Israel [66].

Environmental co-interventions. Although washing and storage measures are unlikely to cause harm and should be encouraged, high-quality studies assessing the clinical effectiveness of washing clothing and bed linen, storage of items in plastic bags, exposure to sunlight and household spraying are required before these measures can be strongly recommended as adjuncts in the control of scabies. No studies used a control group to assess the effect of environmental interventions for scabies. Twelve studies included washing of clothing and bed linen [34, 39, 40, 43, 47–50, 53, 62–65], two studies included storage of items in plastic bags [22, 65], four studies included exposing items to direct sunlight [39, 47, 49, 53] and one study included household spraying [66], as co-interventions (Table 2).

*Crusted scabies*. Moderate quality evidence supports oral ivermectin with topical keratolytics and topical antiparasitics for crusted scabies (1B) [67, 68]. Comparative trials

are needed to explore more effective treatments. Patients with crusted scabies require intensive supportive treatment (1B) [67, 68]. Coordinated case management in the home may be of benefit (2C) [69].

Directed antimicrobial therapy. Moderate quality evidence from a prospective cohort study of Australian Aboriginal inpatients receiving oral ivermectin at days 0, 14 and 28 and daily topical permethrin alternating with keratolytic therapy (topical urea 10% and lactic acid 5%), found 40% achieved complete cure at 4 weeks [68].

Standard treatment protocols. Moderate-quality evidence from a retrospective study used a standard treatment protocol in Australian Aboriginal inpatients with crusted scabies achieving 55% without recurrence at 8 years [67].

Coordinated case management. Low-quality evidence supports topical BB, regular keratolytics, moisturiser and regular screening for new lesions in home-based case management to prevent crusted scabies [69].

*Fungal skin infections*. Directed antimicrobial therapy. *Tinea capitis*—Moderate quality evidence for griseofulvin, terbinafine and fluconazole having similar efficacy for tinea capitis (1B) [70–73]. *Tinea capitis* is difficult to treat, takes several months and mycological cure is challenging.

High-quality evidence of similar clinical and mycological cure was provided by a multicentre RCT from Guatemala, Chile, Costa Rica, USA and India comparing daily oral fluconazole for 3 or 6 weeks with daily griseofulvin [70]. Low-quality RCT evidence from Iran reported no difference between daily fluconazole or daily griseofulvin at 8 weeks [71]. Low-quality evidence from India found griseofulvin twice daily, fluconazole weekly and terbinafine daily all performed similarly [72]. In addition, all used ketoconazole 2% shampoo and prednisolone prescribed for kerion [72]. From China, low-quality cluster RCT evidence confirmed griseofulvin daily for 4 weeks or terbinafine daily for 2–4 weeks performed similarly [73].

*Tinea corporis*—Low to moderate quality evidence for topical sertaconazole, butenafine, miconazole or clotrimazole over other agents for tinea corporis (2C) [74–77]. Low-quality evidence that oral alternatives for tinea corporis are terbinafine or fluconazole (2C) [78]. Although the systematic review on topical treatments for tinea corporis recommends topical terbinafine as a first-line agent [17], no high-quality studies from resource-limited contexts were available to evaluate. Most included trials came from dermatology outpatient clinics in India or

Iran. Community setting, population level evidence is needed for tinea corporis treatment.

Moderate quality RCT evidence from Iran confirmed similar clinical cure at 8 weeks for topical butenafine compared with topical clotrimazole [76] and similar cure rates at 4 weeks for topical miconazole and topical sertaconazole [74]. Moderate quality RCT evidence from India found sertaconazole outperformed miconazole with 62% and 45% cured at 2 weeks respectively,  $P < 0.05$  [75]. Low-quality evidence from India found topical clotrimazole and topical amorolfine were comparable [79] and that topical sertaconazole was superior to topical butenafine [77]. Similarly, very low-quality pilot RCT evidence from India found superiority of topical sertaconazole over topical terbinafine or topical luliconazole for clinical cure and symptom relief [80]. Very low-quality RCT evidence also found no difference between topical sertaconazole and topical terbinafine [81] and that topical terbinafine and topical luliconazole could not be differentiated [82]. Similarly, low-quality RCT evidence from India found that daily oral terbinafine or weekly fluconazole achieved similar clinical cures [78] and topical butenafine was no better than weekly fluconazole combined with topical Whitfield's ointment (3% salicylic acid and 6% benzoic acid) at 4 weeks [83]. Low-quality evidence from a prospective cohort of Australian Aboriginal people with tinea corporis and tinea unguium found daily oral terbinafine cured 32% [84].

**Tinea unguium/onychomycosis**—For tinea unguium, moderate to high-quality evidence recommends oral terbinafine (1A) [85–87], with no added benefit of combination topical therapy in resource-limited settings (1B) [85, 88]. Surgical avulsion prior to treatment of onychomycosis is not recommended (2D) [88]. High-quality studies assessing photodynamic therapy (PDT) regimens for tinea unguium are required to determine the utility of this therapy in resource-limited settings.

High-quality RCT evidence from India trialled two different dosing regimens of terbinafine and showed no difference [85, 86]. Low-quality RCT evidence from Brazil found monthly or second monthly dosing of oral terbinafine had similar outcomes [87] and photodynamic therapy (PDT) every 15 days for 6 months was superior to weekly oral fluconazole [89]. No additional benefit of topical nail lacquer over oral terbinafine alone was found in moderate quality evidence [85, 88].

**Mass drug administration.** No studies assessed the effect of antifungal MDAs on the prevalence of fungal skin infections.

**Complimentary/alternative therapy.** Further studies are needed to assess the role of aloe vera gel, as only very low-quality evidence from one study is available [90].

**Communicable disease prevention and control.** No studies assessed the effect of communicable disease control practices on fungal infections on which to base relevant recommendations for resource-limited settings.

**Hygiene practices.** Daily soap use may be of benefit in the treatment of tinea capitis and tinea corporis. This is recommended in combination with anti-fungal treatment (2C) [91].

From Tanzania, low-quality RCT evidence found mycological cure at 2 months to be similar with either daily washing with triclosan soap or placebo [91].

**Infrastructure including high-quality water supply, swimming pools and housing improvement for skin infections.** **Water provision.** An adequate supply of water for washing and cleaning will reduce the burden of impetigo and scabies (2C) [92]. From studies in remote Australian Indigenous communities, the installation of community swimming pools may assist in the prevention of impetigo, along with other health benefits (2C) [93–95]. No studies assessed the effect of quality water supply or swimming pools on scabies or tinea on which to base recommendations for resource-limited settings.

Low-quality evidence from Panama found that when unlimited, high-quality water was compared to a community with a limited water supply, declines in scabies and impetigo incidence were reported [92]. Low-quality evidence from three studies in Australian Aboriginal communities found a small benefit following the installation of swimming pools for impetigo and skin infections [93–95].

**Housing improvement programmes.** Programmes to improve housing may assist in the prevention and control of skin infections in resource-limited populations (2C) [96, 97].

Low-quality evidence from a housing intervention evaluation of remote Australian Aboriginal communities, found construction of new, standardised housing and the demolition of uninhabitable dwellings did not change the prevalence of skin infections at 10 months [96]. Low-quality evidence from a study that ran for 12 years showed reductions in skin infections following household improvements based on health and safety priorities in a 'survey and fix methodology.' [97]

## Discussion

This is the first systematic review to comprehensively inform treatment, public health control and areas for future research in the control of skin infections using evidence generated in and from settings where skin infection burden is the highest. High-quality evidence for treatment of the individual and community with scabies and for the individual with impetigo is synthesised for inclusion into evidence-based guidelines. Similarly, high-quality evidence for comprehensively addressing scabies and impetigo concurrently is presented, with further studies needed to determine the measurable benefit of additional interventions over treatment alone. The integration of oral antibiotics for treatment of impetigo, use of oral ivermectin or topical permethrin MDA for scabies in endemic or outbreak settings and community education and health promotion activities in skin health programmes are supported by the evidence and should form the basis of skin control programmes when needed. Evidence gaps include community control of dermatophyte infections and targeted environmental health interventions to improve skin health.

Progress towards the streamlined integration of data collection on skin infections when planning MDAs for other infections needs ongoing prioritisation. MDA for trachoma and yaws with azithromycin [98–100] may also reduce the burden of impetigo [61], whilst ivermectin MDA for lymphatic filariasis [101] and scabies [57] will reduce scabies and impetigo prevalence [61] as part of the roadmap towards defeating neglected tropical diseases [102]. This pragmatic, evidence-based strategy is now being tested in larger populations with results awaited (ACTRN12618000461291p) to inform whether community control of scabies will prevent severe skin infections.

For impetigo, duration of treatment, the role of topical therapy and added benefit of comprehensive skin disease control programmes over treatment alone are gaps in the literature. Whilst 3 or 5 days of cotrimoxazole for impetigo treatment in resource-limited settings is effective [26], more comparison studies are needed to optimise treatment duration and utility of cheap, widely available, palatable alternative agents in high-burden contexts. Cephalexin for up to 10 days remains in guidelines for impetigo, yet this is lengthy, costly and may be impractical with no evidence supporting its use for impetigo in high-burden contexts. Unlike developed settings where topical mupirocin and fusidic acid are recommended [16], there are currently no trials using topical antibiotics for impetigo in high burden settings. Results from New Zealand comparing topical antibiotics or antiseptics with placebo are awaited [ACTRN1261000356460].

Knowledge gaps identified include the patient preference for agent to treat scabies, and the additional benefit of comprehensive control programmes for scabies above treatment alone. Topical permethrin has more rapid reduction in symptoms [40, 42] but requires a private space in which to apply the cream to the full body. Conversely, clinical response is slower, but ease of administration and overall community efficacy in MDA support the use of ivermectin [57]. Future studies should address the role of a second dose of ivermectin in asymptomatic individuals as unhatched eggs are refractory to ivermectin [103]. Moxidectin shows promise for future human scabies trials as it has a longer half-life and is ovicidal [104].

Most studies assessing antifungal treatments were from dermatology OPD in middle-income country hospitals, which limits the external validity to other resource-limited settings. Studies assessing the effectiveness of topical and oral (for severe disease) treatments of tinea in a range of resource-limited populations would be of benefit to make recommendations applicable to real life and uncontrolled settings at the individual and population level. Future integration of treatment of tinea into comprehensive skin disease control programmes that address scabies and impetigo may be a way forward.

Despite practical advantages, we found limited evidence for environmental interventions to control skin infections. Although sound attempts to evaluate housing programmes have been made [96, 97], we remain unable to recommend small-scale environmental interventions due to a lack of comparative studies. For example, no studies compared household spraying with no intervention to eradicate the scabies mite. Similarly, there was no evidence for hot washing of clothing compared to not washing clothing. Although environmental measures are unlikely to cause harm in combination with treatment of the skin infection, research is needed to determine any measurable benefit above standard treatment to inform environmental health teams tasked with managing scabies outbreaks, clinicians managing skin infections or governments and communities intending to include environmental policy recommendations in comprehensive skin health programmes in endemic areas.

Although 1759 non-duplicate studies were found for potential inclusion in this systematic review, most were excluded prior to the final appraisal of 81 studies meeting the full inclusion criteria (see Figure 1). This is the complete synthesis of available literature on these four skin conditions. It is possible that restriction to English language publications or being unable to find the full text publication has been a limitation in the scope of this, although <30 full-text studies were excluded for this reason.

## Conclusions

A summary of the evidence-based recommendations for skin infections in high-burden contexts also highlights the need for further rigorous, experimental studies to fill the evidence gaps. Pragmatic, practical, high-quality, well-funded RCTs are essential in the settings where the findings will have external validity if meaningful progress is to be made towards reducing the gap in skin health outcomes between the rich and poor. Acknowledging that RCTs may present ethical issues for some groups [105], robust observational studies of appropriately funded public health interventions can be tested across large populations with designs that control for confounders and in meaningful partnership with the communities under study using participatory research methods.

## Acknowledgements

We wish to thank the following for assistance with the conduct of this review: Marianne Mullane and Claudia Sampson for secretarial support; Aleisha Anderson, Ingrid Duff, Claire Ferguson, Myra Hardy, Therese Kearns, Ella Meumann, Lauren Thomas, Georgia Walker and Daniel Yeoh for data extraction contributions.

## References

- Andrews RM, McCarthy J, Carapetis JR, Currie BJ. Skin disorders, including pyoderma, scabies, and tinea infections. *Pediatr Clin North Am* 2009; 56: 1421–1440.
- Walton SF, Currie BJ. Problems in diagnosing scabies, a global disease in human and animal populations. *Clin Microbiol Rev* 2007; 20: 268–279.
- Mahe A, Hay RJ. *Epidemiology and Management of Common Skin Diseases in Children in Developing Countries*. World Health Organisation: Geneva, 2005.
- Yeoh DK, Anderson A, Cleland G, Bowen AC. Are scabies and impetigo “normalised”? A cross-sectional comparative study of hospitalised children in northern Australia assessing clinical recognition and treatment of skin infections. *PLoS Negl Trop Dis* 2017; 11: e0005726.
- Bowen AC, Mahe A, Hay RJ *et al.* The Global Epidemiology of Impetigo: a systematic review of the population prevalence of impetigo and pyoderma. *PLoS ONE* 2015; 10: e0136789.
- Romani L, Steer AC, Whitfield MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. *Lancet Infect Dis* 2015; 15: 960–967.
- Hay RJ, Johns NE, Williams HC *et al.* The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. *J Invest Dermatol* 2014; 134: 1527–1534.
- Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *Lancet Infect Dis* 2005; 5: 685–694.
- Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 2015; 28: 603–661.
- van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in *Staphylococcus aureus* Bacteremia. *Clin Microbiol Rev* 2012; 25: 362–386.
- McMullan BJ, Bowen A, Blyth CC *et al.* Epidemiology and mortality of *Staphylococcus aureus* bacteremia in Australian and New Zealand Children. *JAMA Pediatrics* 2016; 170: 979–986.
- Hoy WE, White AV, Dowling A *et al.* Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. *Kidney Int* 2012; 81: 1026–1032.
- McDonald MI, Towers RJ, Andrews RM, Bengier N, Currie BJ, Carapetis JR. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. *Clin Infect Dis* 2006; 43: 683–689.
- Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. *Rev Infect Dis* 1989; 11: 928–953.
- Strong M, Johnstone P. Interventions for treating scabies. *Cochrane Database Syst Rev* 2007; (3): Cd000320.
- Koning S, van der Sande R, Verhagen AP *et al.* Interventions for impetigo. *Cochrane Database Syst Rev* 2012; 1: CD003261.
- El-Gohary M, vanZuuren EJ, Fedorowicz Z *et al.* Topical antifungal treatments for tinea cruris and tinea corporis. *Cochrane Database Syst Rev* 2014; (8): Cd009992.
- FitzGerald D, Grainger RJ, Reid A. Interventions for preventing the spread of infestation in close contacts of people with scabies. *Cochrane Database Syst Rev* 2014; (2): Cd009943.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6: e1000097.
- May P, Bowen A, Tong S *et al.* Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. *Syst Rev* 2016; 5: 162.
- Higgins JPTaG, editor. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. The Cochrane Collaboration; 2011. (Available from: <http://handbook.cochrane.org>) [updated March 2011].
- Talukder K, Talukder MQK, Farooque MG *et al.* Controlling scabies in madrasahs (Islamic religious schools) in Bangladesh. *Public Health* 2013; 127: 83–91.
- Wong LC, Amega B, Connors C *et al.* Outcome of an interventional program for scabies in an Indigenous community. *Med J Aust* 2001; 175: 367–370.
- Wong LC, Amega B, Barker R *et al.* Factors supporting sustainability of a community-based scabies control program. *Australas J Dermatol* 2002; 43: 274–277.
- Schmeller W, Dzikus A. Skin diseases in children in rural Kenya: long-term results of a dermatology project within

P. J. May *et al.* Treatment and prevention of impetigo, scabies and tinea

- the primary health care system. *Br J Dermatol* 2001; 144: 118–124.
26. Bowen AC, Tong SY, Andrews RM *et al.* Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. *Lancet* 2014; 384: 2132–2140.
  27. Tong SY, Andrews RM, Kearns T *et al.* Trimethopim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: a pilot randomised controlled trial. *J Paediatr Child Health* 2010; 46: 131–133.
  28. Faye O, Hay RJ, Diawara I, Mahe A. Oral amoxicillin vs. oral erythromycin in the treatment of pyoderma in Bamako, Mali: an open randomized trial. *Int J Dermatol* 2007; 46(Suppl 2): 19–22.
  29. Nicolle LE, Postl B, Urias B, Ling N, Law B. Outcome following therapy of group A streptococcal infection in schoolchildren in isolated northern communities. *Can J Public Health* 1990; 81: 468–470.
  30. Luby S, Agboatwalla M, Schnell BM, Hoekstra RM, Rahbar MH, Keswick BH. The effect of antibacterial soap on impetigo incidence, Karachi, Pakistan. *Am J Trop Med Hyg* 2002; 67: 430–435.
  31. Luby SP, Agboatwalla M, Feikin DR *et al.* Effect of hand-washing on child health: a randomised controlled trial. *Lancet* 2005; 366: 225–233.
  32. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. *Indian J Dermatol Venereol Leprol* 2012; 78: 605–610.
  33. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. *Ann Parasitol* 2013; 59: 79–84.
  34. Zargari O, Golchali J, Sobhani A *et al.* Comparison of the efficacy of topical 1% lindane vs 5% permethrin in scabies: a randomized, double-blind study. *Indian J Dermatol Venereol Leprol* 2006; 72: 33–36.
  35. Pourhasan A, Goldust M, Rezaee E. Treatment of scabies, permethrin 5% cream vs. crotamiton 10% cream. *Ann Parasitol* 2013; 59: 143–147.
  36. Goldust M, Rezaee E, Raghifar R, Naghavi-Behzad M. Comparison of permethrin 2.5% cream vs. Tenutex emulsion for the treatment of scabies. *Ann Parasitol* 2013; 59: 31–35.
  37. Goldust M, Rezaee E, Raghiafar R. Topical ivermectin versus crotamiton cream 10% for the treatment of scabies. *Int J Dermatol* 2014; 53: 904–908.
  38. Mytton O, McGready R, Lee S *et al.* Safety of benzyl benzoate lotion and permethrin in pregnancy: a retrospective matched cohort study. *BJOG* 2007; 114: 582–587.
  39. Sungkar S, Agustin T, Menaldi SL *et al.* Effectiveness of permethrin standard and modified methods in scabies treatment. *Med J Indonesia* 2014; 23: 93–98.
  40. Sharma R, Singal A. Topical permethrin and oral ivermectin in the management of scabies: a prospective, randomized, double blind, controlled study. *Indian J Dermatol Venereol Leprol* 2011; 77: 581–586.
  41. Goldust M, Rezaee E, Hemayat S. Treatment of scabies: comparison of permethrin 5% versus ivermectin. *J Dermatol* 2012; 39: 545–547.
  42. Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies. *Ann Parasitol* 2013; 59: 189–194.
  43. Mapar MA, Mali B. The comparison of oral ivermectin and topical Lindane in the treatment of scabies. *Iranian J Dermatol* 2008; 11: 147–150.
  44. Goldust M, Rezaee E, Raghifar R, Naghavi-Behzad M. Ivermectin vs. lindane in the treatment of scabies. *Ann Parasitol* 2013; 59: 37–41.
  45. Mohebbipour A, Saleh P, Goldust M *et al.* Comparison of oral ivermectin vs. lindane lotion 1% for the treatment of scabies. *Clin Exp Dermatol* 2013; 38: 719–723.
  46. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. *Ann Parasitol* 2015; 61: 79–84.
  47. Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. *J Paediatr Child Health* 2002; 38: 401–404.
  48. Ly F, Caumes E, Ndaw CAT, Ndiaye B, Mahé A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. *Bull World Health Organ* 2009; 87: 424–430.
  49. Sule HM, Thacher TD. Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. *Am J Trop Med Hyg* 2007; 76: 392–395.
  50. Haar K, Romani L, Filimone R *et al.* Scabies community prevalence and mass drug administration in two Fijian villages. *Int J Dermatol* 2014; 53: 739–745.
  51. Mohammed KA, Deb RM, Stanton MC, Molyneux DH. Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis – a rapid assessment methodology to assess impact. *Parasites and Vectors* 2012; 5: 299.
  52. Abedin S, Narang M, Gandhi V, Narang S. Efficacy of permethrin cream and oral ivermectin in treatment of scabies. *Indian J Pediatr* 2007; 74: 915–916.
  53. Agrawal S, Puthia A, Kotwal A, Tilak R, Kunte R, Kushwaha AS. Mass scabies management in an orphanage of rural community: An experience. *Med J Armed Forces India* 2012; 68: 403–406.
  54. Andrews RM, Kearns T, Connors C *et al.* A regional initiative to reduce skin infections amongst aboriginal children living in remote communities of the Northern Territory, Australia. *PLoS Negl Trop Dis* 2009; 3: e554.
  55. Carapetis JR, Connors C, Yarmirr D, Krause V, Currie BJ. Success of a scabies control program in an Australian aboriginal community. *Pediatr Infect Dis J* 1997; 16: 494–499.
  56. Taplin D, Porcelain SL, Meinking TL *et al.* Community control of scabies: a model based on use of permethrin cream. *Lancet* 1991; 337: 1016–1018.

P. J. May *et al.* Treatment and prevention of impetigo, scabies and tinea

57. Romani L, Whitfield MJ, Koroivueta J *et al.* Mass drug administration for scabies control in a population with endemic disease. *N Engl J Med* 2015; **373**: 2305–2313.
58. Kearns TM, Speare R, Cheng AC *et al.* Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian aboriginal community. *PLoS Negl Trop Dis* 2015; **9**: e0004151.
59. Lawrence G, Leafasia J, Sheridan J *et al.* Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. *Bull World Health Organ* 2005; **83**: 34–42.
60. Marks M, Taotao-Wini B, Satorara L *et al.* Long term control of scabies fifteen years after an intensive treatment programme. *PLoS Negl Trop Dis* 2015; **9**: e0004246.
61. Shelby-James TM, Leach AJ, Carapetis JR, Currie BJ, Mathews JD. Impact of single dose azithromycin on group A streptococci in the upper respiratory tract and skin of Aboriginal children. *Pediatr Infect Dis J* 2002; **21**: 375–380.
62. Avila-Romay A, Alvarez-Franco M, Ruiz-Maldonado R. Therapeutic efficacy, secondary effects, and patient acceptability of 10% sulfur in either pork fat or cold cream for the treatment of scabies. *Pediatr Dermatol* 1991; **8**: 64–64.
63. Oyelami OA, Onayemi A, Oyedeji OA, Adeyemi LA. Preliminary study of effectiveness of Aloe vera in scabies treatment. *Phytother Res* 2009; **23**: 1482–1484.
64. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R. Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition. *PLoS Negl Trop Dis* 2009; **3**: e444.
65. Garcia C, Iglesias D, Terashima A, Canales M, Gotuzzo E. Use of ivermectin to treat an institutional outbreak of scabies in a low-resource setting. *Infect Control Hosp Epidemiol* 2007; **28**: 1337–1338.
66. Kanaaneh HA, Rabi SA, Badarneh SM. The eradication of a large scabies outbreak using community-wide health education. *Am J Public Health* 1976; **66**: 564–567.
67. Davis JS, McGloughlin S, Tong SY, Walton SF, Currie BJ. A novel clinical grading scale to guide the management of crusted scabies. *PLoS Negl Trop Dis* 2013; **7**: e2387.
68. Huffam SE, Currie BJ. Ivermectin for *Sarcoptes scabiei* hyperinfestation. *Int J Infect Dis* 1998; **2**: 152–154.
69. Lokuge B, Kopczyński A, Woltmann A *et al.* Crusted scabies in remote Australia, a new way forward: lessons and outcomes from the East Arnhem Scabies Control Program. *Med J Aust* 2014; **200**: 644–648.
70. Foster KW, Friedlander SF, Panzer H, Ghannoum MA, Elewski BE. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. *J Am Acad Dermatol* 2005; **53**: 798–809.
71. Ladan D, Maryam A, Payman J. Comparison of the efficacy of fluconazole and griseofulvin in tinea capitis. *Iranian J Dermatol* 2005; **8**: e88-pe92.
72. Chander G, Pooja A, Vikas M. Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis. *Int J Dermatol* 2012; **51**: 455–458.
73. Deng S, Hu H, Abliz P *et al.* A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China. *Mycopathologia* 2011; **172**: 365–372.
74. Ghaninejad H, Gholami K, Hashemi P *et al.* Sertaconazole 2% cream vs. miconazole 2% cream for cutaneous mycoses: a double-blind clinical trial. *Clin Exp Dermatol* 2009; **34**: e837-9.
75. Sharma A, Saple DG, Surjushe A *et al.* Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. *Mycoses* 2011; **54**: 217–222.
76. Singal A, Pandhi D, Agrawal S, Das S. Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: A randomized, double-blind trial. *J Dermatol Treat* 2005; **16**: 331–335.
77. Thaker SJ, Mehta DS, Shah HA, Dave JN, Mundhava SG. A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2% sertaconazole and topical 1% butenafine in tinea infections of skin. *Indian J Dermatol* 2013; **58**: 451–456.
78. Amit K, Navin B, Priyamvada S, Monika S. A comparative study of mycological efficacy of terbinafine and fluconazole in patients of Tinea corporis. *Int J Biomed Res* 2013; **4**: 603–607.
79. Manasi B, Ghosh AK, Sukumar B, Das KD, Gangopadhyay DN. Comparative evaluation of effectiveness and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. *Indian J Dermatol* 2011; **56**: 657–662.
80. Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. *Indian J Dermatol* 2013; **58**: 34–38.
81. Choudhary SV, Bisati S, Singh AL, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. *Indian J Dermatol* 2013; **58**: 457–460.
82. Lakshmi CPV, Bengalorkar GM, Kumar VS. Clinical efficacy of topical terbinafine versus topical luliconazole in treatment of tinea corporis/tinea cruris patients. *Brit J Pharm Res* 2013; **3**: 1001–1014.
83. Thaker SJ, Mehta DS, Shah HA, Dave JN, Kikani KM. A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield's ointment+oral fluconazole versus topical 1% butenafine in tinea infections of skin. *Indian J Pharmacol* 2013; **45**: 622–624.
84. Koh KJ, Parker CJ, Ellis DH, Pruium B, Leysley L, Currie BJ. Use of terbinafine for tinea in Australian Aboriginal communities in the Top End. *Australas J Dermatol* 2003; **44**: 243–249.
85. Amit J, Sharma RP, Garg AP. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. *Indian J Dermatol Venereol Leprol* 2007; **73**: 393–396.



P. J. May *et al.* **Treatment and prevention of impetigo, scabies and tinea**

86. Pravesh Y, Archana S, Deepika P, Shukla D. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: a randomized double-blind trial. *Indian J Dermatol Venereol Leprol* 2015; **81**: 363–369.
87. Succi IB, Bernardes-Engemann AR, Orofino-Costa R. Inter-mittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study. *Mycoses* 2013; **56**: 327–332.
88. Grover C, Bansal S, Nanda S, Reddy BSN, Kumar V. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. *Br J Dermatol* 2007; **157**: 364–368.
89. Souza LWF, Souza SVT, Botelho ACC. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. *Dermatol Ther* 2014; **27**: 43–47.
90. Chuku EC, Azonwu O, Ugbomeh PA. Control of Tinea (ringworm) using Aloe vera gel in Rivers State. *Acta Agromonica Nigeriana* 2006; **7**: 1–5.
91. Dinkela A, Ferie J, Mbata M, Schmid-Grendelmeier M, Hatz C. Efficacy of triclosan soap against superficial dermatomycoses: a double-blind clinical trial in 224 primary school-children in Kilombero District, Morogoro Region, Tanzania. (Special issue: Global theme issue on poverty and health development.). *Int J Dermatol* 2007; **46**(Suppl.2): 23–28.
92. Ryder RW, Reeves WC, Singh N *et al.* The childhood health effects of an improved water supply system on a remote Panamanian island. *Am J Trop Med Hyg* 1985; **34**: 921–924.
93. Carapetis JR, Johnston F, Nadjamerrek J, Kairupan J. Skin sores in Aboriginal children. *J Paediatr Child Health* 1995; **31**: 563.
94. Lehmann D, Tennant MT, Silva DT *et al.* Benefits of swimming pools in two remote Aboriginal communities in Western Australia: intervention study. *BMJ* 2003; **327**: 415–419.
95. Silva DT, Lehmann D, Tennant MT, Jacoby P, Wright H, Stanley FJ. Effect of swimming pools on antibiotic use and clinic attendance for infections in two Aboriginal communities in Western Australia. *Med J Aust* 2008; **188**: 594–598.
96. Bailie RS, Stevens M, McDonald EL. The impact of housing improvement and socio-environmental factors on common childhood illnesses: a cohort study in Indigenous Australian communities. *J Epidemiol Community Health* 2012; **66**: 821–831.
97. Aboriginal Environmental Health U. *Closing the Gap: 10 Years of Housing for Health in NSW. An Evaluation of a Healthy Housing Intervention.* NSW Department of Health: Sydney, 2010.
98. Marks M, Vahi V, Sokana O *et al.* Impact of community mass treatment with azithromycin for trachoma elimination on the prevalence of yaws. *PLoS Negl Trop Dis* 2015; **9**: e0003988.
99. Harding-Esch EM, Sillah A, Edwards T *et al.* Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. *PLoS Negl Trop Dis* 2013; **7**: e2115.
100. Mitja O, Houine W, Moses P *et al.* Mass treatment with single-dose azithromycin for yaws. *N Engl J Med* 2015; **372**: 703–710.
101. Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, Magesa SM. Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. *PLoS Negl Trop Dis* 2010; **4**: e696.
102. Ortu G, Williams O. Neglected tropical diseases: exploring long term practical approaches to achieve sustainable disease elimination and beyond. *Infect Dis Poverty* 2017; **6**: 147.
103. Mahe A. Mass drug administration for scabies control. *N Engl J Med* 2016; **374**: 1689.
104. Mounsey KE, Bernigaud C, Chosidow O, McCarthy JS. Prospects for Moxidectin as a new oral treatment for human scabies. *PLoS Negl Trop Dis* 2016; **10**: e0004389.
105. Zumla A, Costello A. Ethics of healthcare research in developing countries. *J R Soc Med* 2002; **95**: 275–276.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Table S1.** List of studies included in the systematic review.

**Table S2.** Risk of bias table with overall quality ratings using the GRADE approach for included experimental and controlled studies

**Table S3.** Risk of bias table with overall quality rating using the GRADE approach for included observational studies

**Table S4.** Method of application of topical scabicides in 29 included studies

**Appendix S1.** Definitions for Indigenous peoples and Income groupings used

**Appendix S2.** Evidence Summary and Recommendations for skin infection-related research to guide practice in resource-limited settings.

**Data S1.** PRISMA Checklist

**Corresponding Author** Asha Bowen, Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, 100 Roberts Road, Subiaco, WA 6008, Australia. Tel.: +61 412 608 003; E-mail: Asha.bowen@telethonkids.org.au